PLATE-Seq for genome-wide regulatory network analysis of high-throughput screens

Erin C. Bush¹,², Forest Ray¹, Mariano J. Alvarez¹,³, Ronald Realubit*¹,², Hai Li¹,², Charles Karan¹,², Andrea Califano¹,²,⁴,⁵ & Peter A. Sims¹,²,⁴

Pharmacological and functional genomic screens play an essential role in the discovery and characterization of therapeutic targets and associated pharmacological inhibitors. Although these screens affect thousands of gene products, the typical readout is based on low complexity rather than genome-wide assays. To address this limitation, we introduce pooled library amplification for transcriptome expression (PLATE-Seq), a low-cost, genome-wide mRNA profiling methodology specifically designed to complement high-throughput screening assays. Introduction of sample-specific barcodes during reverse transcription supports pooled library construction and low-depth sequencing that is 10- to 20-fold less expensive than conventional RNA-Seq. The use of network-based algorithms to infer protein activity from PLATE-Seq data results in comparable reproducibility to 30 M read sequencing. Indeed, PLATE-Seq reproducibility compares favorably to other large-scale perturbational profiling studies such as the connectivity map and library of integrated network-based cellular signatures.
High-throughput screening (HTS) represents a key component of drug discovery and a critical technology used throughout biomedical research. Due to cost and complexity, however, most screens are still performed using low-complexity reporters, such as cell viability, inhibition of specific enzymes, binding affinity, protein-protein interactions, mitochondrial respiration, and cell growth. In contrast, there is increasing interest in coupling HTS with genome-wide reporters, which may provide a more comprehensive portrait of drug activity.

Indeed, a key advantage of genome-wide reporters is their more universal nature; specifically, the ability to test hypotheses that may not have been considered at the time of assay development. For instance, the same data from gene expression profiling of cellular perturbations have been used effectively to predict compound mechanism-of-action (MoA) and sensitivity in specific cellular contexts, as well as to identify synergistic drug combinations, with similar MoA, and candidates for drug repositioning. Indeed, when incorporated in an HTS setting, genome-wide profiles can report on virtually any genes or pathways of interest, without requiring an a priori commitment.

Unfortunately, due to their relatively high cost and labor-intensive nature, genome-wide expression profiles have not been incorporated as primary reporters in HTS campaigns. A few exceptions, such as connectivity map (CMap), represent proof-of-concept studies rather than scalable approaches and have either been restricted to a handful of cell lines or replaced by methodologies that report on a limited number of genes (e.g., Luminex L1000 reporters).

To address this challenge, we introduce a new approach that combines a highly scalable and multiplexed RNA-Seq protocol (PLATE-Seq) with regulatory network analysis. Collectively, this integrative and fully automated pipeline allows accurate, reproducible characterization of the proteins, whose activity is affected by a library of bioactive compounds. The proposed approach involves two key concepts: (a) a strategy for barcoding and pooling cDNA libraries to substantially reduce the cost and complexity of multi-sample RNA-Seq and (b) the use of network-based algorithms for the highly reproducible inference of protein activity from low-depth RNA-Seq profiles (0.5–2 M reads). Taken together, this combination supports a >tenfold cost reduction with virtually no reduction in assay accuracy and reproducibility, compared to standard depth (30 M read) sequencing.

This translates into a dramatic increase in gene reporter dimensionality for HTS applications—from a few observables to a genome-wide repertoire—at a total reagent cost of ~$15 per sample.

### Results

**PLATE-Seq technology.** Recent advances in multiplexed and single-cell RNA-Seq have led to significant increases in cost effectiveness and scalability of gene expression profiling. These methodologies introduce sample-specific sequence barcodes into cDNA prior to library construction, allowing early pooling of cDNA from many samples and a proportional decrease in reagent and labor costs. They are also optimally suited to automation, allowing straightforward integration into HTS pipelines for analysis of RNAi or small molecule perturbations in a multi-well format. Here we use automated liquid handling to

---

**Fig. 1 Schematic illustration of PLATE-Seq workflow.** After conducting a screen in multi-well plates, we lyse the cells and capture mRNA from the cell lysate using an oligo(dT)-coated capture plate. The purified mRNA is then reverse transcribed with barcoded, adapter-linked oligo(dT) primers and the resulting cDNA is pooled. All of these steps are automated. The remaining steps, which take place on a single pooled sample, are conducted manually and include cDNA purification, second-strand synthesis, and PCR enrichment. Molecular-level schematic for constructing 3′-end PLATE-Seq libraries. After reverse transcription with oligo(dT), second-strand synthesis of the pooled cDNA is accomplished using random hexamer primers prior to PCR enrichment of the barcoded pool.
introduce lysis buffer, capture polyadenylated mRNA with an oligo(dT)-grafted plate, and deliver well-specific, barcoded oligo (dT) primers to every sample in a multi-well plate (Fig. 1a). After reverse transcription, the cDNA in each well contains a specific barcode sequence on its 5’ end and a common adapter, such that all samples can be combined into a single pool for purification and concentration. We then use Klenow large fragment for pooled second-strand synthesis from adapter-linked random primers. Because this polymerase lacks strand displacement and 5’ to 3’ exonuclease activities, each cDNA molecule produces at most, one second-strand synthesis product containing the sample barcode (Fig. 1b). Finally, the pooled library is enriched in a single

Fig. 2 PLATE-Seq performance. a Histogram of genes symbols detected per sample for a 96-well PLATE-Seq experiment in BT20 cells. b Histogram of uniquely mapped reads per sample for the experiment in a. c We pooled half of the sample from every six wells for conventional RNA-Seq with 30 M raw reads (Illumina TruSeq). Here we show a histogram of gene symbols detected per sample for each six-well TruSeq pool and for the sum of the corresponding six PLATE-Seq samples. d Same as c for uniquely mapped reads per sample. e Gene detection saturation curve for PLATE-Seq samples based on random subsampling. The points represent the average over all 96 wells and the error bars are deviations s.e.m. f Same as e but for each six-well TruSeq pool and for the sum of the corresponding six PLATE-Seq samples. g MDS clustering of PLATE-Seq and TruSeq samples based on differentially expressed genes identifying using the PLATE-Seq replicates for each drug compared to vehicle control samples. The PLATE-Seq replicates for each drug cluster together and also with the corresponding TruSeq samples. h Heat map showing the top 40 most differentially expressed genes based on PLATE-Seq of mitoxantrone- and idarubicin-treated BT20 cells measured with both PLATE-Seq and TruSeq. The two drugs are both topoisomerase II inhibitors and have similar gene expression signatures. i Same as h but with differentially active proteins as inferred using VIPER. Note that TOP2A, the gene that encodes the target of the two drugs, is strongly deactivated. j Gene expression of differentially active proteins inferred using VIPER. Most of these genes are not differentially expressed and some are difficult to detect with PLATE-Seq, yet VIPER can still infer their activities.
PCR prior to sequencing. The resulting libraries represent the 3’ ends of mRNAs and are sequenced to a depth of 0.5–2 M raw reads per sample.

PLATE-Seq performance. To characterize the performance of PLATE-Seq, we conducted a fully automated, 96-well screen to profile BT20 breast cancer cells following treatment with seven well-characterized small-molecule perturbagens (plus DMSO controls) and 12 replicates per condition. Figure 2a, b shows the detected gene and uniquely mapped read distributions across the 96-well plate samples. On average, we detected ~10,200 genes per sample from ~670,000 uniquely mapped reads from ~10,000 cells per well. To compare PLATE-Seq to conventional RNA-Seq, we processed some of the replicates using the Illumina TruSeq protocol, to a standard depth of ~30 M reads. Indeed, unlike gene expression profiles using VIPER is highly robust to correlation of VIPER-inferred activity profiles using different expression profiling technologies. For instance, drugs such as aprepitant, gemcitabine, and albendazole, which had minimal effects on BT20 cells, were clustered together. In contrast, strongly bioactive drugs, such as crizotinib and bortezomib, produced distinct but highly reproducible and technology-independent clusters. Drugs with similar MoA, such as the topoisomerase II inhibitors mitoxantrone and idarubicin, clustered together. Finally, we performed gene set enrichment analysis (GSEA) of significantly altered genes detected by PLATE-Seq in the TruSeq differential expression analysis. For all gene sets, we found highly significant enrichment of the PLATE-Seq genes in the appropriate direction (Supplementary Fig. 1). Hence, both PLATE-Seq and conventional RNA-Seq produce comparable gene expression signatures following drug perturbation.

We also investigated whether the gene expression signatures associated with each drug were comparable between the two methods. We used DESeq2 (ref. 18) to identify differentially expressed genes (q < 0.05) to identify differentially expressed genes (q < 0.05) between each set of drug-treated and vehicle-control replicates measured by PLATE-Seq and projected a matrix of fold changes computed from both PLATE-Seq and TruSeq across these genes using multidimensional scaling (Fig. 2g). As expected, replicates associated with distinct drug treatments cluster together, consistent with their tissue-specific activity and independent of profiling technology. For instance, drugs such as aprepitant, gemcitabine, and albendazole, which had minimal effects on BT20 cells, were clustered together. In contrast, strongly bioactive drugs, such as crizotinib and bortezomib, produced distinct but highly reproducible and technology-independent clusters. Drugs with similar MoA, such as the topoisomerase II inhibitors mitoxantrone and idarubicin, clustered together. Finally, we performed gene set enrichment analysis (GSEA) of significantly altered genes detected by PLATE-Seq in the TruSeq differential expression analysis. For all gene sets, we found highly significant enrichment of the PLATE-Seq genes in the appropriate direction (Supplementary Fig. 1). Hence, both PLATE-Seq and conventional RNA-Seq produce comparable gene expression signatures following drug perturbation.

In Alvarez et al.19, we showed that assessing protein activity from gene expression profiles using VIPER is highly robust to low-depth sequencing. Indeed, unlike gene expression profiles, whose correlation degraded rapidly with decreasing sequencing depth, Spearman’s correlation of VIPER-inferred activity profiles was virtually unaffected between 0.1 and 30 M reads19. This is because VIPER infers protein activity from expression of its tissue-specific transcriptional targets, as identified by the ARACNe algorithm. Thus, VIPER integrates dozens to hundreds of gene expression measurements to infer activity of a single protein, effectively averaging out noise resulting from low-depth sequencing19.

Fig. 3 Comparison of PLATE-Seq to CMap and LINCS. a Mean CV vs. relative mean expression for PLATE-Seq U87 184-compound screen and CMap GPL3921 microarray platform duplicates. b Same as a for PLATE-Seq U87 screen and CMap GPL96 microarray platform. c Same as a for PLATE-Seq U87 screen and LINCS/L1000 screen. d CV histogram across genes for duplicates in the PLATE-Seq U87 screen and CMap GPL3921 microarray platform. e Same as d for PLATE-Seq U87 screen and CMap GPL96 microarray platform. f Same as d for PLATE-Seq U87 screen and LINCS/L1000 screen.

ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-017-00136-z

NATURE COMMUNICATIONS | 8:105 | DOI: 10.1038/s41467-017-00136-z | www.nature.com/naturecommunications
Protein activity inference with PLATE-Seq. To demonstrate the practical utility of this theoretical advantage when using low-depth PLATE-Seq assays, we used VIPER to compute differential activity of ~6000 regulatory proteins, including ~2000 transcription factors and ~4000 signaling proteins, following treatment with the topoisomerase II inhibitors mitoxantrone and idarubicin\(^9\). Figure 2h shows the gene expression signatures of the top 40 genes most differentially expressed following perturbation by either drug, based on PLATE-Seq. As expected from Fig. 2g, there is excellent agreement between PLATE-Seq and TruSeq. To identify key regulatory proteins responsible for the pharmacological effects of these two drugs and thus comprising their MoAs, we analyzed both the PLATE-Seq and the TruSeq profiles with VIPER. We used our recently published breast cancer-specific gene regulatory network\(^{19}\) generated by ARACNe analysis\(^{20, 21}\) of gene expression profiles from the breast cancer cohort collected by The Cancer Genome Atlas consortium\(^{22, 23}\). Figure 2i shows the top 40 most differentially activated proteins following mitoxantrone or idarubicin treatment, based on PLATE-Seq. Critically, VIPER-inferred protein activity was highly reproducible across PLATE-Seq and TruSeq samples (see Supplementary Fig. 2 for GSEA). Furthermore, TOP2A, the gene that encodes the target of both drugs, was among the most deactivated regulatory proteins by VIPER analysis, along with several other key cell cycle control proteins (e.g., CEPNF, FOXM1, CCNA2, BUB1B, and CENPK). Finally, Fig. 2j shows the top 40 most differentially expressed genes following mitoxantrone or idarubicin treatment, based on PLATE-Seq. As expected from previous studies\(^{19, 24}\), the gene expression signatures associated with these top 40 differentially active proteins. Consistent with previous studies\(^{19, 23, 24}\), many of these proteins, including cell cycle regulators, that play an important role in the MoA of these drugs, such as FOXM1, CCNA2, and TOP2A, are not among the top 40 most differentially expressed genes. This effectively demonstrates that the combination of PLATE-Seq and VIPER analysis produces differential protein activity profiles that are remarkably robust, independent of the low-sequencing depth.

Comparison of PLATE-Seq to CMap and LINCS. Previous efforts have attempted to elucidate MoA based on gene expression alterations in cell lines\(^2, 7\). CMap represents a first seminal attempt at this approach based on microarray profiling of cell lines treated with several hundred compounds\(^2\). To increase scalability, library of integrated network-based cellular signatures (LINCS) implemented the Luminex L1000, which reports on ~1000 representative markers from which broader expression profiles could be computationally inferred\(^3, 25\). However, these two data sets, which represent the current state-of-the-art, require a trade-off between cost/efficiency and coverage. Therefore, we reasoned that PLATE-Seq might provide a solution to this trade-off by supporting a genome-wide reporter assay while leveraging the broader dynamic range of RNA-Seq compared to microarrays and the ability to profile >tenfold more genes than the L1000 at a comparable cost.

To compare PLATE-Seq to these technologies, we conducted a 4 × 96-well screen with 184 clinically relevant compounds plus vehicle controls (Supplementary Table 1) in U87 cells in duplicate. We then systematically compared the gene-level noise distribution we obtained to those of the CMap and LINCS/L1000 data sets. Figure 3a–c shows how the average coefficients of variation across replicates vary with average expression level for PLATE-Seq in comparison to CMap data obtained with the GPL3921 microarray platform, CMap with the GPL96 platform, and LINCS/L1000, respectively. Similarly, Fig. 3d–f shows the overall distributions of average coefficients of variation for these same comparisons. Despite the significantly lower costs associated with PLATE-Seq, we obtain comparable noise distributions to CMap. In addition, we point out that although the noise in the LINCS data set is twofold lower than in the PLATE-Seq screen (for duplicates taken from GSE70138), measurements are only made for 978 genes (>tenfold fewer than in PLATE-Seq, which is a genome-wide measurement). We also show that the dynamic range for signal in PLATE-Seq is comparable to these alternative methods by calculating the fold-change distribution across each expression measurement and perturbation relative to vehicle controls (Supplementary Fig. 4). Hence, PLATE-Seq compares favorably to previous approaches and may offer an effective, low-cost platform for assessing compound MoA similarity.

Discussion

Small molecule perturbations induce complex, cell-context-specific alterations that ultimately affect thousands of genes. This challenges the use of low-complexity reporter assays in HTS to elucidate MoA. In contrast, RNA-Seq represents a high-dimensional assay that is particularly well suited for compound MoA elucidation\(^{19, 26}\), similarity analysis\(^2, 7\), and synergy analysis\(^9\) especially when using network-based methods that may pinpoint the key regulatory targets and effectors. However, conventional RNA-Seq involves independent library construction for each sample and deep sequencing, making its application to HTS prohibitively expensive and poorly suited to automation. For instance, at an average cost of ~$300 per profile, screening a library of ~4000 compounds across two time points, concentrations, and replicates would cost ~$10 M in reagents. However, when combined with automated, pooled library preparation and the tenfold reduction in sequencing depth made possible by leveraging VIPER, the reagent cost for the same 4000-compound campaign would be less than ~$0.5 M, a 20-fold reduction.

A possible limitation of the approach is its dependence on regulon quality for accurate inference of protein activity. Using large-scale benchmarks, we have shown that differential activity is accurately predicted for >70% of transcriptional regulators and ~60% of signaling proteins\(^9\). However, if specific proteins of interest are poorly characterized in the assay, ad hoc regulons can be generated by combining DNA-binding assays and expression profiles following perturbation\(^27\). In addition, as computational reverse engineering methods improve, accuracy of protein activity inference will increase. In this case, data from previous screens can simply be re-analyzed using the improved models to produce more accurate and extensive protein-activity profile coverage, thus avoiding obsolescence of PLATE-Seq data sets.

We expect PLATE-Seq to have broad pharmacological applications, including elucidation of compound MoA and synergy, support for drug re-positioning, and precision medicine approaches where MoA is matched to patient-specific disease dependencies. Finally, while we focused mainly on drug screening, PLATE-Seq is equally amenable to RNAi, CRISPR-Cas9, and cDNA screening assays. This highly scalable and economical approach integrates HTS with high-dimensional analysis of RNA expression and protein activity, revealing the connections between cellular perturbations and genome-wide regulatory interactions.

Methods

Cell culture and drug perturbation assays. BT20 epithelial breast carcinoma cells were cultured in white 96-well tissue culture-treated plates (Greiner 655083) at a starting density of 8000 cells per well in 100 μl of eagle’s minimum essential medium supplemented with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin. After 24 h of incubation, the plates were treated with drugs. Each drug was dosed at the concentration at which the cells were 80% viable after 48 h of treatment. After 6 h of treatment, the medium was replaced with 100 μl of FBS supplemented with 10% DMSO and the plates were frozen at –80 °C prior to PLATE-Seq. After thawing for PLATE-Seq, cells were washed twice with phosphate-buffered saline (PBS) prior to lysis.
Automated PLATE-Seq. Cells are lysed for PLATE-Seq in Buffer TCLI (Qiagen) supplemented with 2-mercaptoethanol in 96-well plates. We transfer 30 µl of cell lysate from each 96-well plate with total mRNA extraction protocol to a 96-well plate with total mRNA extraction protocol to the Illumina Index Capture Plate (Qiagen) and added 1 µl of 1:10 dilution of ERCC Ex-Ext Spike-Ins (ThermoFisher) to a subset of the sample wells. The plate is then centrifuged at 295 × g for 1 min to eliminate air bubbles followed by incubation for 90 min at room temperature with shaking at 200 rpm. Lysate is then removed from the oligo(dT) capture plate and wells are washed three times with Buffer TCW (Qiagen) using the 96 CO-RE Head of a Hamilton Microlab STAR automated liquid handling system. After drying the plate, mRNA is then eluted by adding 30 µl of elution buffer (nuclease-free water supplemented with 0.4 U µl⁻¹ SUPERFiNase (ThermoFisher), incubation at 65 °C for 5 min, and incubation at room temperature for 5 min. mRNA samples are then transferred to a new PCR plate (Hard-Shell PCR plate, 96-well, Bio-Rad) using sterile-filter 96-well, 50 µl tips on the Hamilton STAR.

To anneal primers for reverse transcription, 3 µl of 100 µM adapter-linked oligo (dT) primers are added to each well along with 10 µl of 5x ProtoScript RT Buffer (New England BioLabs) with the Hamilton STAR CO-RE Head and 100 µl channel pipetting system (see Supplementary Table 2 for “PLATEseq oligo(dTBC) sequences). The plate is then heated to 94 °C for 2 min and placed immediately on ice for 5 min. The remaining components of the reverse transcription master mix including 0.5 µM of each dNTP, 10 mM DTT, 35.8 U of Protoscript II Reverse Transcriptase (New England Biolabs), and water are then added to bring the final reaction volume to 50 µl per well. The plate is then centrifuged at 295 × g for 1 min and incubated at 42 °C for 2 h. At this point, the samples can optionally be frozen at −80 °C.

To remove excess primer, 1 µl of a fourfold dilution of Exonuclease I (New England BioLabs) is added to each sample. The Exonuclease I reaction is incubated at 25 °C for 1 h. To hydrolyze the RNA, we add 20 µl of a 1:1 mixture of 1 M sodium hydroxide and 0.5 M EDTA to each well and incubate at 65 °C for 15 min. The wells are then pooled together into a single tube to which 90 µl of 12 M hydrochloric acid are added to neutralize the sample. At this point, the pooled, neutralized sample can be optionally frozen at −80 °C

The pooled, neutralized sample is purified and concentrated using a Qiagen MinElute column using a vacuum apparatus according to the manufacturer’s instructions, and pooled cDNA is eluted in 15 µl of nuclease-free water. For second strand synthesis, 1 µl 100 nM dNTP mixture and 1 µl of 100 µM adapter-linked random hexamer primers are added to the pooled cDNA sample (see Supplementary Table 2 for “PLATEseq second_strand” primer sequence). The mixture is then heated to 70 °C for 2 min and immediately placed on ice for 5 min. Next, 2 µl of NEB Buffer 2 (New England Biolabs) and 1 µl of Klenow large fragment DNA polymerase (New England Biolabs) are added and the reaction is incubated at room temperature for 20 min. The reaction is then stopped by addition of EDTA to a final concentration of 50 µM the double-stranded cDNA is purified with two rounds of bead clean up using AMPure XP beads (Beckman Coulter) at a 1:1 bead-to-sample ratio. Finally, the double-stranded cDNA pool is amplified by PCR using Phusion DNA Polymerase (New England Biolabs) with 0.5 µM Illumina R1 primer and Illumina R1X primer (where x is a number indicating the Illumina index). The thermocycling protocol begins with 98 °C for 30 s followed by 10–12 cycles of 98 °C for 15 s, 62 °C for 15 s, and 72 °C for 30 s with a final extension at 72 °C.

Samples are sequenced on an Illumina HiSeq 4000 using a 75 cycle paired-end run. Custom sequencing primers were used in each cycle version 2 sequencing. Custom sequencing primers were used in each cycle version 2 sequencing. Relative protein activity was inferred from the single-sample gene expression signatures using the VIPER algorithm.

Large-scale PLATE-Seq screen in U87 cells. U87 cells were plated in a 384-well plate at 200,000 cells ml⁻¹ in 20 µl of media for a final count of 4000 cells per well. After 24 h, the Labcyte Echo 530 Liquid Handling system was used to dispense drugs at concentrations resulting in 20% growth inhibition (Supplementary Table 1). After 24 h of drug treatment, media was removed and cells were washed with PBS. Cells were then lysed in 20 µl of Buffer TCLI (Qiagen) containing 1% β-mercaptoethanol. Following the z-pattern of quadrants for a 384-well plate, 20 µl of lysate from quadrant 1, and 20 µl of lysate from quadrants 3 and 4 were pooled into one of a well of a 96-well TurboCapture plate (mRNA TurboCapture Plate, Qiagen) for a total of 40 µl of lysate in each well during the mRNA capture step. PLATE-Seq was then followed as above. The resulting pooled libraries were sequenced on an Illumina HiSeq 4000 using a 50-cycle SBS kit and a PE cluster kit. Read 1 comprised 18 cycles and Read 2 comprised 50 cycles.

Comparison of PLATE-Seq screens to CMap and LINCS. In Fig. 3, we compare the coefficient of variation (CV) between PLATE-Seq, CMap, and LINCS screening data sets. For PLATE-Seq, we took our U87 screen (4 × 96 wells with 184 drugs plus controls) data set and computed the CV and average expression for each gene in each duplicate measurement. We then plotted the average CV vs. average expression across all duplicates for each gene in Fig. 3a–c and distribution of these same average CVs in Fig. 3d–f. For CMap, we took all duplicates from screens conducted in MCF7 (processed average difference values available on the Gene Expression Omnibus under accession GSE5258) and applied the same calculations as we did for PLATE-Seq. We analyzed microarray data generated using the Gene Expression Omnibus. The resulting expression data set from the Gene Expression Omnibus under accession GSE70138 (Level 2 data corresponding to gene expression values for genes that were measured directly) for
~26,000 randomly selected duplicates and applied the same calculation to the ~1000 genes measured directly on the L1000 platform. In Supplementary Fig. 4, we compare PLATE-Seq, CMap, and LINCS in terms of the fold change in each gene expression measurement across all perturbations relative to their respective vehicle controls. We calculated these distributions using the same expression matrices that we used for the CV comparisons.

**Note on cells lines.** We note that BT20 cells are on the ICLAC list of commonly misidentified cell lines, but that the identity of a particular cell line is immmaterial to the conclusions of our technical assessment of PLATE-Seq. Nonetheless, the BT20, U87, and LnCAP cell lines used these studies were all obtained from ATCC, which authenticates the cell lines it provides by STR testing. Internally, we tested all of the cell lines for mycoplasma prior to use.

**Code availability.** The VIPER algorithm is available at [http://califano.c2b2.columbia.edu/viper/](http://califano.c2b2.columbia.edu/viper/).

**Data availability.** All of the raw and processed data associated with this study are available at the Gene Expression Omnibus under accession GSE97460.

Received: 26 October 2016 Accepted: 5 June 2017
Published online: 24 July 2017

**Acknowledgements**

P.A.S. was supported by Grant K01EB016071 from NIH/NIBIB. A.C. was supported by grant R35CA197745 from NIH/NCI. A.C. was also supported by grants S10OD021764 and S10OD012351 from the Office of the Director of NIH, and both A.C. and P.A.S. were supported by grant U54CA209997 from NIH/NCI.

**Author contributions**

PLATE-Seq was conceived and designed by A.C. and P.A.S. Experimental methodology for PLATE-Seq was developed by E.C.B., F.R. and P.A.S. Analytical methodology for network-based analysis of PLATE-Seq was developed by M.J.A. and A.C. Data processing and analysis were conducted by E.C.B., F.R., M.J.A., P.A.S. and A.C. HTS experiments were conducted by F.R., R.R., H.L. and C.K. Automated PLATE-Seq was developed and implemented by R.R., C.K. and E.C.B. E.C.B., F.R., M.J.A., R.R., H.L., C.K., A.C. and P.A.S. wrote the paper.

**Additional information**

Supplementary Information accompanies this paper at doi:10.1038/s41467-017-00136-z.

**Competing interests:** M.J.A. is chief scientific officer of DarwinHealth Inc. A.C. is a founder of DarwinHealth Inc. The remaining authors declare no competing financial interests.

Reprints and permission information is available online at [http://npg.nature.com/reprintsandpermissions/](http://npg.nature.com/reprintsandpermissions/).

**Publisher’s note:** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.